Doppler ultrasonography with perfusion software and contrast agent injection can be used to predict which patients with metastatic renal cell cancer will respond to treatment with the antiangiogenic drug sorafenib, according to a study presented at the 2005 American Society of Clinical Oncology meeting in Orlando.
Doppler ultrasonography with perfusion software and contrast agent injection can be used to predict which patients with metastatic renal cell cancer will respond to treatment with the antiangiogenic drug sorafenib, according to a study presented at the 2005 American Society of Clinical Oncology meeting in Orlando.
"This sonographic method is original. B-mode imaging of tissue, on the one hand, and the use of microbubbles in different colors and advanced dynamic flow, on the other hand, can be visualized simultaneously but independently," said lead author Dr. Bernard J. Escudier.
Escudier and colleagues from the Institute Gustave-Roussy in Villejuif, France, and from Bayer Pharmaceuticals in West Haven, CT, tested the imaging technique to measure tumor response in 30 patients with metastatic renal cell cancer. They were enrolled in a double-blind placebo controlled phase III study of sorafenib.
Researchers prospectively evaluated tumor vascularization with the unique imaging technique at baseline and after three and six weeks on sorafenib or placebo in patients with tumor targets accessible to ultrasound.
Two radiologists evaluated the percentage of contrast uptake in each tumor. Results with Doppler ultrasonography with perfusion software were compared against CT scan studies at six weeks and with progression-free survival.
Preliminary results showed a decrease in tumor vascularization in 10 of 28 patients at three weeks and in 10 of 25 patients at six weeks.
"Overall, the combination of a decrease in contrast uptake of more than 10% with a stability or decrease in tumor volume significantly predicts progression-free survival in renal cell cancer. These criteria seem to be particularly predictive of benefit in patients treated with sorafenib," Escudier said.
For more information from the Diagnostic Imaging archives:
Contrast-enhanced ultrasound achieves new breakthroughs
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
What New Research Reveals About ChatGPT and Ultrasound Detection of Thyroid Nodules
March 13th 2024In a comparison of image-to-text large language models (LLMs), ChatGPT 4.0 offered a 95 percent sensitivity rate and an 83 percent AUC that were comparable to that of two senior radiologists and one junior radiologist interacting with LLM to differentiate between malignant and benign thyroid nodules on ultrasound.
ECR Study Finds Mixed Results with AI on Breast Ultrasound
March 6th 2024While adjunctive use of AI led to significantly higher specificity and accuracy rates in detecting cancer on breast ultrasound exams in comparison to unassisted reading by breast radiologists, researchers noted that 12 of 13 BI-RADS 3 lesions upgraded by AI were ultimately benign, according to research presented at the European Congress of Radiology.